Hospital Group
Approval of the world’s first BNCT drug Steboronine®
It was gratifying that Japan Ministry of Health, Labour and Welfare approved the world’s first boron drug Steboronine® developed by STELLA PHARMA CORPORATION on March 25, 2020. 
STELLA PHARMA CORPORATION conducted Phase Two trial (company-initiated clinical trial) in collaboration with Sumitomo Heavy Industries and Southern TOHOKU BNCT Research Center since December 2015. Steboronine® will be utilized in Boron Neutron Capture Therapy (BNCT), which not only gives another option to the oncologists, but benefits the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer.


The world’s first AB-BNCT system obtained an approval from Japanese government
We are pleased to announce that the world’s first AB-BNCT system (BNCT System NeuCure™ & BNCT dose calculation program NeuCure™ Dose Engine, Sumitomo Heavy Industries, Ltd.) obtained medical device approval from Japan Ministry of Health, Labor and Welfare on March 11, 2020.
Clinical application will start once STELLA PHARMA CORPORATION obtains the boron-based drug application approval. We expect to commence treatment for international patients with advanced inoperable or recurrent head and neck cancer in June 2020. Treatment packages and fees will be announced shortly.


STHG signed an MOU with Pantai Jerudong Specialist Centre
On January 18, 2020, Southern TOHOKU Hospital (STHG), Japan and Pantai Jerudong Specialist Centre (PJSC), Brunei signed an MOU to facilitate collaboration in the areas of the exchange of staff training and mutual interest.
The signing ceremony took place at Brunei’s Ministry of Finance and Economy building. Dr. Sadayoshi Watanabe, Superintendent of Tokyo General Hospital under STHG, and Dr. Haji Mohd Amin Liew bin Abdullah, Chairman of PJSC signed the MOU on behalf of their representative institutions. Prof. Kanichi Seto, senior advisor to STHG and Koriyama International Exchange Ambassador, was present to witness the momentous occasion.
PJSC is a private healthcare specialist centre consisting of The Brunei Cancer Centre (TBCC), Brunei Neuroscience Stroke and Rehabilitation Centre (BNSRC), and Maxillofacial, Facial Plastic and Reconstructive Surgery Centre (MFPRSC). It provides medical and rehabilitative treatments for patients with cancer, stroke and other neurological problems. Both the institutions look forward to a beneficial and fruitful relationship in the foreseeable future.


Southern TOHOKU General Hospital neurosurgical fellowship program
Southern TOHOKU General Hospital is a member of the World Federation of Neurosurgical Societies (WFNS) Foundation to offer fellowship program for young neurosurgeons from around the world since 2015. 


Founded in 1995, WFNS comprises 103 member countries on 5 continents and represents over 3,000 neurosurgeons worldwide.


Up to date, we have received four neurosurgeons from India, Iraq, Pakistan and Yemen. The doctor from Yemen is undertaking fellowship program and will complete in November 2018.


The goal of this program is to provide a multidisciplinary exposure to Neurosurgery and offer an opportunity to delve into further area of study, particularly for young neurosurgeons from developing countries including Iraq and Pakistan. 


Southern TOHOKU General Hospital will continuously collaborate with WFNS to offer neurosurgeons a supportive environment with rich leaning experience.

Dr. Ayman Ali Mohammed Mayas from Yemen